Thursday, March 29, 2018

US FDA News: FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse

FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse
Read more: FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse